3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Melanoma
5
Lung Neoplasms
3
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
38
Nivolumab
24
atezolizumab
10
Ipilimumab
7
Carboplatin
6
avelumab
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Cyclophosphamide
5
fludarabine
4
cabozantinib
4
Specimen Handling
4
Pemetrexed
4
regorafenib
3
Interleukin-2
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
lenvatinib
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Biopsy
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Thoracic
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled